Home/Pipeline/REBIF (interferon beta-1a)

REBIF (interferon beta-1a)

Multiple Sclerosis

ApprovedActive (Lifecycle Management)

Key Facts

Indication

Multiple Sclerosis

Phase

Approved

Status

Active (Lifecycle Management)

Company

EMD Serono

About EMD Serono

EMD Serono is a well-established, commercial-stage biopharmaceutical company and a key regional pillar of the global Merck KGaA healthcare group. With a legacy dating back to 1971, it has built a strong commercial presence in high-need therapeutic areas, particularly reproductive health, neurology, and oncology. The company's strategy involves commercializing the global parent's pipeline in North America while also engaging in targeted business development to expand its portfolio. As a subsidiary of a large, diversified multinational, it benefits from significant R&D resources and financial stability while focusing on specialty care markets with significant unmet needs.

View full company profile

Therapeutic Areas

Oncology Neurology Reproductive Health Immunology

Other Multiple Sclerosis Drugs

Drug	Company	Phase	Status
Mimotopes-003	Mimotopes	Preclinical	Active
SPU-16	Silo Pharma	Preclinical	Research
Electroceutical® Therapy	Endonovo Therapeutics	Research	Active
IMX39	Imunexus Therapeutics	Preclinical	Active
BTK allosteric inhibitor	Acellera	Pre-clinical	Early Hit
CLS12311	Cellerys	Phase 2	Active
Interferon-beta variants	Heligenics	Pre-clinical	Active
G-NK cells	Indapta Therapeutics	Phase 1	Active
MS Biomarker Research	Rune Labs	Research	Active
AVT001	Avotres	Phase 2b	Active
Undisclosed MS Program	Astoria Biologica	Pre-clinical	Active
PV-3212	Provid Pharma	Pre-clinical	Active